Disease relevance of Digotab

• With beta-acetyldigoxin there was no statistically significant difference between patients with cirrhosis and healthy volunteers [1].
• According to our findings there is more danger of digitalis toxicity in patients with cirrhosis of the liver on a standard dosage of metildigoxin than on a standard dosage of beta-acetyldigoxin [1].

High impact information on Digotab

• P-glycoprotein-mediated transport of digitoxin, alpha-methyldigoxin and beta-acetyldigoxin [2].
• In summary, these data provide evidence that not only digoxin, but also digitoxin, alpha-methyldigoxin and beta-acetyldigoxin are substrates of P-glycoprotein [2].
• Cytostatic drugs reduce the rate and extent of beta-acetyldigoxin absorption attributable to reversible damage of the gastrointestinal mucosa [3].
• We used a psychophysical method, an automatically evaluated Farnsworth's Munsell 100-Hue Test, to detect color vision deficiencies in patients who received beta-methyldigoxin or beta-acetyldigoxin for at least 4 weeks as maintenance therapy [4].
• Bioavailability of beta-acetyldigoxin after single and repeated doses of tablets and solution [5].

Associations of Digotab with other chemical compounds

• Whereas particle size, dissolution rate and lipophilic properties have been identified as determinants for absorption of digitalis glycosides, little is known about P-glycoprotein transport characteristics of digitalis glycosides such as digitoxin, alpha-methyldigoxin, beta-acetyldigoxin and ouabain [2].
• The bioavailability of tablet formulations averages about 60% for digoxin, 75% for beta-acetyldigoxin, and 75% for beta-methyldigoxin [6].

References